Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome II
- Development stage
- Unknown
- Lead developer
- CSPC Ouyi Pharmaceutical
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Irinotecan liposome II is a liposomal formulation of the topoisomerase I inhibitor irinotecan, developed by CSPC Pharmaceutical Group (specifically its subsidiary CSPC Ouyi Pharmaceutical). It was approved by China's National Medical Products Administration (NMPA) in September 2023 under the brand name Duoenda. The (II) designation distinguishes this specific formulation from other liposomal irinotecan products. It is indicated for use in combination with 5-fluorouracil and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma who have progressed following gemcitabine-based therapy. The liposomal delivery system is designed to enhance the drug's stability in circulation and increase its accumulation in tumor tissues, where the prodrug irinotecan is converted into the active metabolite SN-38. SN-38 then inhibits DNA topoisomerase I, leading to lethal DNA strand breaks and tumor cell apoptosis.
- Brand names
- Duoenda
- Other names
- Irinotecan Liposome Injection (II)伊立替康脂质体注射液(II)liposomal irinotecan II
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposome II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome II.